AS Grindeks pazi\u0146o par noz\u012bm\u012bgu pav\u0113rsienu uz\u0146\u0113muma produktu portfe\u013ca papla\u0161in\u0101\u0161an\u0101 \u2013 Apvienotaj\u0101 Karalist\u0113 veiksm\u012bgi re\u0123istr\u0113ts betametazona valer\u0101ta kr\u0113ms. Re\u0123istr\u0101cija veikta Apvienot\u0101s Karalistes nacion\u0101l\u0101s proced\u016bras ietvaros, un tas ir pirmais uz\u0146\u0113muma kortikostero\u012bdu produkts, kas ien\u0101k \u0161aj\u0101 tirg\u016b. Betametazona valer\u0101ta kr\u0113mu ir izstr\u0101d\u0101jusi AS Grindeks Izstr\u0101des noda\u013cas komanda, iev\u0113rojot Eiropas Z\u0101\u013cu a\u0123ent\u016bras normat\u012bv\u0101s pras\u012bbas.<\/p>\n\n\n\n
Betametazona valer\u0101ta kr\u0113ma ra\u017eo\u0161ana ir veiksm\u012bgi p\u0101rcelta uz Tallinna Farmaatsiatehase AS (Tallinas farmaceitisko r\u016bpn\u012bcu), kas apr\u012bkota ar modern\u0101m, specializ\u0113t\u0101m kortikostero\u012bdu ra\u017eo\u0161anas l\u012bnij\u0101m. Tallinas farmaceitisk\u0101s r\u016bpn\u012bcas ra\u017eo\u0161anas iecirknis ir uzb\u016bv\u0113ts, lai nodro\u0161in\u0101tu kvalit\u0101ti, ra\u017eo\u0161anas efektivit\u0101ti un atbilst\u012bbu, saska\u0146\u0101 ar normat\u012bvajiem standartiem gan pa\u0161u ra\u017eotaj\u0101m z\u0101l\u0113m, gan AS Grindeks partneru produktiem.<\/p>\n\n\n\n
Tallinas farmaceitisk\u0101s r\u016bpn\u012bcas ra\u017eo\u0161anas jauda: vair\u0101k nek\u0101 5 miljoni t\u016bbi\u0146u gad\u0101, nodro\u0161inot augstas precizit\u0101tes ra\u017eo\u0161anu sp\u0113c\u012bgas iedarb\u012bbas akt\u012bvaj\u0101m viel\u0101m.<\/p>\n\n\n\n
Papildus AS Grindeks koncerna produktu portfelim, Tallinas farmaceitisk\u0101 r\u016bpn\u012bca ir vado\u0161ais partneris farmaceitisko produktu l\u012bgumra\u017eo\u0161an\u0101. Pateicoties modernaj\u0101m tehnolo\u0123ij\u0101m un atbilsto\u0161ajai jaudai, Tallinas farmaceitisk\u0101s r\u016bpn\u012bcas ra\u017eotne ir ide\u0101li piem\u0113rota starptautiskajiem partneriem, lai ra\u017eotu m\u012bkst\u0101s z\u0101\u013cu formas.<\/p>\n","protected":false},"excerpt":{"rendered":"
AS Grindeks pazi\u0146o par noz\u012bm\u012bgu pav\u0113rsienu uz\u0146\u0113muma produktu portfe\u013ca papla\u0161in\u0101\u0161an\u0101 \u2013 Apvienotaj\u0101 Karalist\u0113 veiksm\u012bgi re\u0123istr\u0113ts betametazona valer\u0101ta kr\u0113ms. Re\u0123istr\u0101cija veikta Apvienot\u0101s Karalistes nacion\u0101l\u0101s proced\u016bras ietvaros,…<\/p>\n","protected":false},"author":22,"featured_media":12354,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-12349","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/12349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=12349"}],"version-history":[{"count":2,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/12349\/revisions"}],"predecessor-version":[{"id":12366,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/12349\/revisions\/12366"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/12354"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=12349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=12349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=12349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}